14.38  0.05 (0.35%)		08-21 16:00
Open: 14.33 High: 14.41 Volume: 745,058		Pre. Close: 14.33 Low: 14.28 Market Cap: 974(M)

Short term
Mid term
Targets	6-month :	18.56	1-year :	21.68
Resists	First :	15.89	Second :	18.56
Pivot price	14.11
Supports	First :	13.08	Second :	11.35
MAs	MA(5) :	14.31	MA(20) :	13.84
	MA(100) :	10.76	MA(250) :	8.89
MACD	MACD :	0.6	Signal :	0.7
%K %D	K(14,3) :	57.6	D(3) :	56.4
RSI	RSI(14): 61.7
52-week	High :	15.89	Low :	6.25

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ BVS ] has closed below upper band by 35.0%. Bollinger Bands are 22.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	14.42 - 14.49	14.49 - 14.55
Low:	14.1 - 14.18	14.18 - 14.26
Close:	14.25 - 14.37	14.37 - 14.49

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Mon, 17 Aug 2026
Bioventus (NASDAQ:BVS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat

Mon, 17 Aug 2026
Bioventus' (BVS) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat

Mon, 10 Aug 2026
The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance - Yahoo Finance

Mon, 10 Aug 2026
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings - Yahoo Finance

Sun, 09 Aug 2026
Sei Investments Co. Boosts Holdings in Bioventus Inc. $BVS - MarketBeat

Sun, 09 Aug 2026
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	68 (M)
Shares Float	34 (M)
Held by Insiders	11.6 (%)
Held by Institutions	77.5 (%)
Shares Short	2,730 (K)
Shares Short P.Month	1,930 (K)

EPS	0.77
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.34
Profit Margin	9.3 %
Operating Margin	12.2 %
Return on Assets (ttm)	5.4 %
Return on Equity (ttm)	25.6 %
Qtrly Rev. Growth	3.7 %
Gross Profit (p.s.)	5.84
Sales Per Share	8.51
EBITDA (p.s.)	1.17
Qtrly Earnings Growth	327.2 %
Operating Cash Flow	97 (M)
Levered Free Cash Flow	68 (M)

PE Ratio	18.43
PEG Ratio	1.7
Price to Book value	4.29
Price to Sales	1.68
Price to Cash Flow	10.14

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.